BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cosentyx (secukinumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cosentyx (secukinumab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07237594-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cosentyx (secukinumab): Phase 1 readout est. (NCT07237594)
DESCRIPTION:Cosentyx (secukinumab)\, phase 1.\nStudy: IL-17 Blockade to Dec
 rease irAEs (REPLAY)\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/secukinumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07237594
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06833112-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT06833112)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4.\nStudy: Interleukin-17 (IL-17
 ) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor
  for the Treatment of Ankylosing Spondylitis\nEstimated primary completion
 : August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/secuki
 numab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06833112
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04239859-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT04239859)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4\, Psoriasis.\nStudy: Outcomes 
 With Treatment and Withdraw of Secukinumab in Patients With Plaque Psorias
 is\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/secukinumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04239859
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cosentyx (secukinumab): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Cosentyx (secukinumab)\, phase 2.\nStudy: Immunosuppressant Man
 agement in Rheumatology Patients Undergoing Elective Total Shoulder Arthro
 plasty\nEstimated primary completion: January 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/secukinumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05622708-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT05622708)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4.\nStudy: A Study of Secukinuma
 b to Evaluate Maintenance of Response in Participants With Non-radiographi
 c Axial Spondyloarthritis Who Achieved Remission\nEstimated primary comple
 tion: 8 February 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/secukinumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05622708
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06398106-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT06398106)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4\, Psoriasis.\nStudy: Proactive
  TDM Versus Standard Use of Biologics in Psoriasis\nEstimated primary comp
 letion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /secukinumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06398106
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06331312-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280508
DTEND;VALUE=DATE:20280509
SUMMARY:Cosentyx (secukinumab): Phase 3 readout est. (NCT06331312)
DESCRIPTION:Cosentyx (secukinumab)\, phase 3.\nStudy: Open-label\, Long-ter
 m Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)\nEstimated p
 rimary completion: 8 May 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/secukinumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06331312
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917247-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Cosentyx (secukinumab): Phase 3 readout est. (NCT07917247)
DESCRIPTION:Cosentyx (secukinumab)\, phase 3.\nStudy: Safety and Efficacy o
 f Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendro
 cyte Glycoprotein Antibody-associated Disease\nEstimated primary completio
 n: 15 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/secuk
 inumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07917247
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770646-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT07770646)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4.\nStudy: A Pragmatic Trial of 
 Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necro
 sis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis\nEstimated p
 rimary completion: 15 September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/secukinumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07770646
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704190-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT07704190)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4.\nStudy: Effect of Secukinumab
  on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome a
 nd Atherosclerotic Cardiovascular Disease\nEstimated primary completion: 3
 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/secu
 kinumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07704190
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489573-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290925
DTEND;VALUE=DATE:20290926
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT07489573)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4\, Hidradenitis Suppurativa.\nS
 tudy: Study of Efficacy and Safety of Secukinumab in Chinese Adult Patient
 s With Moderate to Severe Hidradenitis Suppurativa\nEstimated primary comp
 letion: 25 September 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/secukinumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07489573
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477795-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Cosentyx (secukinumab): Phase 2 readout est. (NCT07477795)
DESCRIPTION:Cosentyx (secukinumab)\, phase 2.\nStudy: Phase II Intervention
 al Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Ta
 kayasu Patients\nEstimated primary completion: 1 October 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/secukinumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07477795
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751238-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Cosentyx (secukinumab): Phase 1 readout est. (NCT06751238)
DESCRIPTION:Cosentyx (secukinumab)\, phase 1\, Psoriatic Arthritis.\nStudy:
  Study to Evaluate the Pharmacokinetics (PK)\, Safety and Tolerability up 
 to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants Wit
 h Juvenile Psoriatic Arthritis (JPsA).\nEstimated primary completion: 31 O
 ctober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/secukinu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06751238
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04638647-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300129
DTEND;VALUE=DATE:20300130
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT04638647)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4.\nStudy: Secukinumab Open Labe
 l Roll-over Extension Protocol\nEstimated primary completion: 29 January 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/secukinumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04638647
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-91@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Cosentyx (secukinumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Cosentyx (secukinumab)\, phase 4\, Psoriasis.\nStudy: Utilizati
 on of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary
  completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/secukinumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07352566
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
